Oxidative stress in non-obese women with polycystic ovarian syndrome

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 7, 2014, Pages

  Desai, Varalakshmi ^a   Prasad, Namburi Rajendra ^b   Manohar, Suchitra Musturu ^a   Sachan, Alok ^a   Lakshmi Narasimha, Srinivasa Rao Pemmaraju Venkata ^a   Bitla, Aparna Rajeshwar Rao ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NARAYANA MEDICAL COLLEGE   (India)

Author keywords

Cardiovascular risk; FRAP; Insulin resistance; Malondialdehyde

Indexed keywords

GLUCOSE; INSULIN; MALONALDEHYDE; URIC ACID;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; NON OBESITY; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84904788198     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/8125.4530     Document Type: Article

References (30)

1. Franks S, Robinson S, Willis DS. Polycystic Ovary Syndrome. N Engl J Med. 1995; 333:883-61.
2. Dunaif A. Insulin resistance and the PCOS: mechanisms and implication for pathogenesis. Endocr Rev. 1997; 18:774-800.
3. Lorenz LB, Wild RA. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin Obstet Gynecol. 2007;50:226-43.
4. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995; 15: 821-26.
5. Victor VM, Rocha M, Bañuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011; 96(10):3115-22.
6. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: From molecular mechanisms to health implications. Antioxid Redox Signal. 2008; 10: 1375-403.
7. Caimi G, Carollo C and Presti RL. Diabetes mellitus: oxidative stress and wine. Curr Med Res Opinion. 2003; 19: 581-86.
8. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27-32.
9. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87:840-4.
10. Supriya P, Bitla AR, Rajendra Prasad N, Rajagopal G, Madhusudhan Rao A, Suchitra MM, et al. Body iron status and association with hyperinsulinaemia and hyperandrogenism in non-obese Indian women with polycystic ovarian syndrome. J Clin Sci Res. 2012;1:2-7.
11. Escobar-Morreale HF1, Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sancho J, San Millán JL. Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care. 2005;28:2042-4.
12. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51:2348-54.
13. Fenkci V, Fenkci S, Yilmaz M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003; 80: 123-27.
14. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34:407-13.
15. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20:3333-40.
16. Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med. 2013;58:107-14.
17. Kusçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009; 88:612-7.
18. Liu J, Zhang D. The role of oxidative stress in the pathogenesis of polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43:187-90.
19. Kandasamy S, Inmozhi Sivagamasundari R, Bupathy A, Sethubathy S, Gobal V. Evaluation of insulin resistance and oxidative stress in obese patients with polycystic ovary syndrome. International J of Applied Biology and Pharma Technology. 2010; 1: 391-98.
20. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol. 2004; 56:1-6.
21. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990; 8:15-9.
22. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70-6.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
24. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336-40.
25. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336:1066-71.
26. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor inhibits signalling from the insulin receptor. Proc Natl Acad Sci USA. 1994;91:4854-58.
27. González F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab. 2012;97:2836-43.
28. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000; 29:1106-14.
29. Verit FF, Erel O. Oxidative stress in non-obese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008; 65:233-39.
30. Quiñónez Zarza C, Silva Ruiz R, Torres Juárez JM. Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome. Ginecol Obstet Mex. 2000; 68:317-22.